RXiBreeze PAP System (RXiBreeze 20C)— 510(k) K253044

Substantially Equivalent

Resvent Medical Technology Co., Ltd.

FDA 510(k) clearance K253044 for RXiBreeze PAP System (RXiBreeze 20C), Substantially Equivalent on 2026-07-23. Applicant: Resvent Medical Technology Co., Ltd.. Device class: 2.

Summary

Resvent Medical Technology's RXiBreeze PAP System (RXiBreeze 20C) is filed under BZD, non-continuous ventilators (respirators). The record doesn't expand "PAP" or give specs.

Class II, 21 CFR 868.5905. Anesthesiology is both the classification panel and the review panel. It came in as a Traditional 510(k).

Resvent filed from Shenzhen, China. The decision came 304 calendar days after FDA received it (September 22, 2025 to July 23, 2026).

Clearance details

Applicant
Resvent Medical Technology Co., Ltd.
Product code
Product code BZD
Device class
Class 2
Regulation
21 CFR 868.5905
Advisory panel
Anesthesiology
Date received
Decision date
Decision
Substantially Equivalent
Clearance type
Traditional
Location
Shenzhen, CN
Download summary PDFView on FDA.gov ↗

Recent devices under product code BZD

view all

Adverse events under product code BZD

product code BZD
Death
4,440
Injury
53,099
Malfunction
213,222
Other
17
Total
270,778

Source: openFDA MAUDE database, through . Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.